These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36585177)

  • 1. Lymph-vascular Space Involvement and/or p53 Overexpression Correlated With the Clinical Outcome of Early-stage Endometrial Cancer Patients Treated With Adjuvant Vaginal Brachytherapy.
    Laliscia C; Gadducci A; Coccia N; Mattioni R; Fuentes T; Caretto M; Pistolesi S; Puccini P; Perrone F; Morganti R; Paiar F
    Anticancer Res; 2023 Jan; 43(1):149-156. PubMed ID: 36585177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
    Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
    Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer.
    Philp L; Tannenbaum S; Haber H; Saini A; Laurent JS; James K; Feltmate CM; Russo AL; Growdon WB
    Gynecol Oncol; 2021 Feb; 160(2):389-395. PubMed ID: 33358198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.
    Bosse T; Peters EE; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Mens JW; Lutgens LC; van der Steen-Banasik EM; Smit VT; Nout RA
    Eur J Cancer; 2015 Sep; 51(13):1742-50. PubMed ID: 26049688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer.
    Dunn EF; Geye H; Platta CS; Gondi V; Rose S; Bradley KA; Anderson BM
    Gynecol Oncol; 2014 Jun; 133(3):494-8. PubMed ID: 24657301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.
    Turner BC; Knisely JP; Kacinski BM; Haffty BG; Gumbs AA; Roberts KB; Frank AH; Peschel RE; Rutherford TJ; Edraki B; Kohorn EI; Chambers SK; Schwartz PE; Wilson LD
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):77-84. PubMed ID: 9422561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel Lymph node Endometrial Cancer Trial).
    Grassi T; Mariani A; Cibula D; Soliman PT; Suman VJ; Weaver AL; Pedra Nobre S; Weigelt B; Glaser GE; Cappuccio S; Abu-Rustum NR
    Int J Gynecol Cancer; 2020 Oct; 30(10):1627-1632. PubMed ID: 32699021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion.
    Son J; Chambers LM; Carr C; Michener CM; Yao M; Beavis A; Yen TT; Stone RL; Wethington SL; Fader AN; Burkett WC; Richardson DL; Staley AS; Ahn S; Gehrig PA; Torres D; Dowdy SC; Sullivan MW; Modesitt SC; Watson C; Veade A; Ehrisman J; Havrilesky L; Secord AA; Loreen A; Griffin K; Jackson A; Viswanathan A; Ricci S
    Int J Gynecol Cancer; 2020 Nov; 30(11):1738-1747. PubMed ID: 32771986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of lymphovascular space invasion in early-stage low-grade endometrioid endometrial cancer: a fifteen-year retrospective Chinese cohort study.
    Sun B; Zhang X; Dong Y; Li X; Yang X; Zhao L; Wang J; Cheng Y
    World J Surg Oncol; 2024 Jul; 22(1):203. PubMed ID: 39080611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer.
    Jin M; Hou X; Sun X; Zhang Y; Hu K; Zhang F
    Int J Gynecol Cancer; 2019 Oct; 29(8):1264-1270. PubMed ID: 31320487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphadenectomy in women with endometrial cancer: aspiration and reality from a radiation oncologist's point of view.
    Foerster R; Kluck R; Arians N; Rieken S; Rief H; Adeberg S; Bostel T; Schlampp I; Debus J; Lindel K
    Radiat Oncol; 2015 Jul; 10():147. PubMed ID: 26179059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pelvic lymphadenectomy as an alternative to adjuvant radiotherapy in early stage endometrial cancer at high risk of recurrent lymphatic metastases (stage I)].
    Amato NA; Partipilo V; Mele F; Boscia F; De Marzo P
    Minerva Ginecol; 2009 Feb; 61(1):1-12. PubMed ID: 19204656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is Substantial Lymphovascular Space Invasion Prognostic in Patients With Pathologically Lymph Node-Negative Endometrial Cancer?
    Pifer PM; Jaishankar S; Bhargava R; Schad MD; Keller A; Musunuru HB; Cohen M; Sukumvanich P; Courtney-Brooks M; Boisen M; Berger JL; Olawaiye A; Lesnock J; Edwards R; Taylor S; Vargo JA; Beriwal S
    Int J Radiat Oncol Biol Phys; 2023 Sep; 117(1):148-153. PubMed ID: 36893818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Chemotherapy versus Radiotherapy in High-risk, Early-stage Endometrioid Endometrial Carcinoma.
    Wu M; Yang YN; Huang YH; Cai J; He XQ; Wang ZH
    Curr Med Sci; 2022 Feb; 42(1):185-191. PubMed ID: 34669113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial.
    Eltabbakh GH; Piver MS; Hempling RE; Shin KH
    Int J Radiat Oncol Biol Phys; 1997 May; 38(2):373-80. PubMed ID: 9226326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?
    Beavis AL; Yen TT; Stone RL; Wethington SL; Carr C; Son J; Chambers L; Michener CM; Ricci S; Burkett WC; Richardson DL; Staley AS; Ahn S; Gehrig PA; Torres D; Dowdy SC; Sullivan MW; Modesitt SC; Watson C; Veade A; Ehrisman J; Havrilesky L; Secord AA; Loreen A; Griffin K; Jackson A; Viswanathan AN; Jager LR; Fader AN
    Gynecol Oncol; 2020 Mar; 156(3):568-574. PubMed ID: 31948730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do vaginal recurrence rates differ among adjuvant vaginal brachytherapy regimens in early-stage endometrial cancer?
    Ager BJ; Francis SR; Do OA; Huang YJ; Soisson AP; Dodson MK; Werner TL; Sause WT; Grant JD; Gaffney DK
    Brachytherapy; 2019; 18(4):453-461. PubMed ID: 31005603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
    Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
    Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
    van den Heerik ASVM; Horeweg N; Nout RA; Lutgens LCHW; van der Steen-Banasik EM; Westerveld GH; van den Berg HA; Slot A; Koppe FLA; Kommoss S; Mens JWM; Nowee ME; Bijmolt S; Cibula D; Stam TC; Jurgenliemk-Schulz IM; Snyers A; Hamann M; Zwanenburg AG; Coen VLMA; Vandecasteele K; Gillham C; Chargari C; Verhoeven-Adema KW; Putter H; van den Hout WB; Wortman BG; Nijman HW; Bosse T; Creutzberg CL
    Int J Gynecol Cancer; 2020 Dec; 30(12):2002-2007. PubMed ID: 33046573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer.
    Garzon S; Grassi T; Mariani A; Kollikonda S; Weaver AL; McGree ME; Petersen IA; Weroha SJ; Glaser GE; Langstraat CL; Amarnath SR; AlHilli MM
    Gynecol Oncol; 2022 Dec; 167(3):444-451. PubMed ID: 36244826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.